Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in store for 2015 from the stem cell crystal ball? There is so much going on that for this […]
Stem Cell Predictions for 2015 Read More »
It’s been a seemingly rather quiet year on the FDA regulatory front in the US when it comes to direct-to-consumer stem cell interventions even as the number of dubious stem cell clinics continues to skyrocket. I requested an interview with the FDA to cover the key pressing issues in this arena. I want to thank
FDA on Key Stem Cell Regulatory Issues & Its Own Research Read More »
StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought
Interview with StemCells Inc. leadership on hot topics Read More »
There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition. They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of
Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS Read More »
A long-standing debate in the commercial stem cell arena has focused on whether stem cells grown in a lab prior to clinical use as a transplantation product are biological drugs subject to full FDA vetting. The alternative view has been that such stem cell products are not drugs, but rather are simple human cellular and
Court in Regenerative Sciences Case: Propagated Stem Cells Are Drugs Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
Stem Cells for Alzheimer’s Disease? Below is an excerpt focused on Alzheimer’s Disease from my new book on stem cells. Stem Cells: An Insider’s Guide, which is targeted to a broad audience of people interested in stem cells. Alzheimer’s Disease (AD) is one of the most devastating illnesses. It destroys the brain, which shrinks over
Book Excerpt: Stem Cells for Alzheimer’s Disease–Are We There yet? Read More »
A new paper suggests a hopeful short-term safety profile of laboratory-grown stem cells for treatment of arthritis, but there are some important limitations to the study too. A debate continues to bubble over whether to classify laboratory-propagated stem cells as biological drugs. A persistent issue has been whether the growth of stem cells in culture
Short-term safety of lab-grown stem cells for arthritis: encouraging, but key caveats Read More »
Today’s post is my no-B.S. guide to the possibility of stem cells for Multiple Sclerosis (MS). There is a great deal of buzz about using stem cells to treat or even cure multiple sclerosis. How much of this stem cell buzz is real hope and how much is hype? Symptoms and standard MS care MS has
A no B.S. guide to stem cells for Multiple Sclerosis (MS) Read More »
What does homologous use mean? Navigating the arena of clinical use of a biologic such as stem cells or differentiated cells made from stem cells can be challenging. There are many important issues including what defines “minimal manipulation” of biologics such as cells. One particular issue that is critically important and has drawn less attention
Time to bone up on homologous use in the stem cell field Read More »